Robert Blum Sells 7,931 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,931 shares of Cytokinetics stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $60.72, for a total transaction of $481,570.32. Following the completion of the sale, the chief executive officer directly owned 391,673 shares of the company’s stock, valued at $23,782,384.56. The trade was a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Cytokinetics Stock Down 0.9%

Shares of Cytokinetics stock opened at $63.63 on Thursday. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The business’s fifty day moving average is $64.02 and its two-hundred day moving average is $60.10. The firm has a market cap of $7.84 billion, a PE ratio of -9.74 and a beta of 0.56.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the company posted ($1.26) earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Earnings/investor call framed a “high‑stakes” commercial launch as Cytokinetics shifts into commercialization — investors see successful market uptake as material revenue upside. Read More.
• Positive Sentiment: An insider exercised options valued at roughly $920k+ as the drug hit the market — often read as insiders monetizing launch value and signaling commercialization is underway. Read More.
• Positive Sentiment: Analyst activity remains constructive: several firms raised price targets and some maintain buy ratings, leaving a consensus target materially above current levels — supportive for medium‑term upside.
• Neutral Sentiment: Reported short‑interest data for early March shows “0” shares and a 0.0 days ratio — this is almost certainly a data/reporting anomaly rather than a real change in short positioning; treat as non‑informative until updated.
• Negative Sentiment: Insider sales on March 9: CEO Robert I. Blum sold 7,931 shares (~$481.6k) and EVPs Fady I. Malik and Andrew Callos sold 2,907 and 2,582 shares respectively at about $60.72 — substantial executives remain holders, but these disclosures look like near‑term profit‑taking and can weigh on sentiment. SEC filings: CEO Form 4 (Read More.), Malik Form 4 (Read More.), Callos Form 4 (Read More.).

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC raised its stake in shares of Cytokinetics by 46.4% in the 4th quarter. Corient Private Wealth LLC now owns 7,044 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 2,231 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Cytokinetics during the 4th quarter worth $657,000. Alpine Global Management LLC purchased a new stake in Cytokinetics during the 4th quarter worth $381,000. Pacer Advisors Inc. increased its holdings in Cytokinetics by 76.5% in the 4th quarter. Pacer Advisors Inc. now owns 27,783 shares of the biopharmaceutical company’s stock valued at $1,765,000 after purchasing an additional 12,043 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Cytokinetics by 30.3% in the 4th quarter. Invesco Ltd. now owns 204,878 shares of the biopharmaceutical company’s stock valued at $13,018,000 after purchasing an additional 47,629 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CYTK shares. Citizens Jmp boosted their target price on shares of Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a report on Wednesday, February 25th. Royal Bank Of Canada increased their price target on shares of Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Truist Financial lifted their price target on shares of Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a report on Tuesday, February 3rd. Needham & Company LLC boosted their price objective on shares of Cytokinetics from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, UBS Group upped their price objective on Cytokinetics from $61.00 to $69.00 and gave the stock a “neutral” rating in a report on Friday, March 6th. Seventeen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.00.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.